ClinicalTrials.gov
public full text
Public Domain
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
cholangiocarcinomaendometrial-cancerhcc-hepatocellular-carcinomahnsccmelanomansclc-non-small-cell-lung-cancerpancreatic-ductal-adenocarcinoma
This is a single-arm, single-center study for multiple tumor indications to evaluate the safety of GV20-0251. The trial uses a 3 + 3 design and enrolls 3-6 patients in the 10 mg/kg and 20 mg/kg dose groups, respectively. The cancer types include solid tumors.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma#1088924
- A Phase I Study of GC101 TIL in Advanced Solid Tumors#1114852
- Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors#1352715
- A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors#827498
- Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma#1261174
Record · ID 1371115
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive